Strategic partnerships Arrowhead has engaged in asset licensing and collaborations (e.g., PNPLA3 licensing to Madrigal). This indicates openness to co-development or out-licensing models, presenting opportunities to propose joint development, regional licensing, or milestone-driven partnerships for RNAi therapies targeting metabolic and liver diseases.

Pipeline focus Active programs in obesity, MASH (PNPLA3/MASH axis), and triglyceride-lowering therapies (AR0-INHBE, plozasiran) suggest strong demand for liver and metabolic disease solutions. Position sales efforts around predefined clinical milestones and companion diagnostics to align with Arrowhead’s clinical milestones.

Competitive landscape Competitors in RNAi and GalNAc-siRNA platforms are intensifying in liver-targeted indications. This creates a sales window to offer differentiated delivery technologies, safety and efficacy data packages, or turnkey program development support to accelerate Arrowhead’s competitive edge.

Recent activity Recent conference appearances and data disclosures at Jefferies and EASL, plus asset divestments (Sarepta deal in 2024, Madrigal licensing in 2026) indicate ongoing strategic pivots. Leverage these signals to align proposals with Arrowhead’s near-term milestones and potential buy-side or license-out opportunities.

Financial and scale signals Revenue in the lower hundreds of millions and a sizeable workforce imply capacity for expanded collaborations and larger programs. Propose enterprise-level partnerships, co-development deals, or CRO/DMO services to support scaled clinical programs and regulatory filings.